| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT05671510 ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors |
Enrollment closed, study ongoing |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07659379 | Gotistobart Long Term Extension (LTE) Study | Advanced Solid Tumor | Not Yet Recruiting |
| NCT05671510 | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Non Small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05446298 | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | Ovarian Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06635785 | Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF… | Advanced Solid Tumor | Recruiting |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in… | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT05682443 | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT06352359 | Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors | Advanced Solid Tumor | Recruiting |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors | Melanoma | Active, Not Recruiting |
| NCT07408258 | Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors | Advanced Solid Tumor | Not Yet Recruiting |